Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: J Immunol. 2009 Nov 16;183(11):7489–7496. doi: 10.4049/jimmunol.0901414

FIGURE 4.

FIGURE 4

Locostatin, a RKIP-specific compound, induces T cell anergy in vitro. A, Splenocytes and LN cells 6 days after immunization as described in legend of Fig. 1 were restimulated in vitro for 5 h with SIINFEKL in the absence or presence of locostatin. Cells were fixed, permeabilized, and stained for IFN-γ, TNF-α and the congenic marker CD45.1. The percentage CD45.1+-gated cells producing IFN-γ and TNF-α is indicated. B, The percentage ± SEM of OT-I cells (CD45.1+) producing IFN-γ and TNF-α from five independent experiments (n = 16) is shown for four incremental doses of locostatin: 0 μM, 6.7 μM, 20 μM, and 60 μM. C, Inhibition of cytokine secretion was tested by adding the 60 μM of locostatin at 0, 10, 60, and 180 min during a 300 min SIINFEKL restimulation. The percentage CD45.1+-gated cells producing IFN-γ and TNF-α is representative of three independent experiments (n = 14).